Pfizer Tops Q3 2026 Estimates, Raises Full-Year EPS Guidance, Names Cecile Guegan Permanent CFO

Pfizer topped Wall Street's third-quarter 2026 estimates, lifted its full-year adjusted earnings guidance, and confirmed Cecile Guegan as permanent chief financial officer, according to CNBC. CNBC cited stronger-than-expected sales of blood thinner Eliquis and targeted cancer drug Padcev, along with Covid products that came in ahead of estimates even as those franchises continue to decline from pandemic-era peaks.

Q3 Results and Guidance Raise

CNBC reported that Pfizer now expects full-year adjusted earnings per share of $2.95 to $3.05, up from its previous guidance range of $2.80 to $3.00. The outlet also noted that the low end of the company's updated revenue range would be roughly flat to slightly down compared with 2025 revenue of $62.6 billion, meaning the guidance still assumes the possibility of a modest year-over-year decline even after the upward revision.

Eliquis and Oncology Drive the Beat

According to CNBC, sales of Eliquis and Padcev "jumped and beat expectations," and the outlet identified those two products as key drivers of the quarter's upside. The available reporting does not break out the specific prescribing, pricing, or volume dynamics behind the jump, so the precise cause of the acceleration in either product line was not detailed in the sources reviewed for this brief.

Separately, Yahoo Finance has described Pfizer's oncology franchise, built through its Seagen acquisition, and its obesity-drug push via the Metsera deal, as giving the company more pipeline optionality than some peers. That characterization speaks to Pfizer's broader portfolio positioning rather than to a specific explanation for this quarter's Eliquis or Padcev strength.

Covid Products Still Beat Forecasts

Even as Covid-related sales continue to decline from pandemic-era peaks, Pfizer's Covid vaccine and Paxlovid both came in ahead of analyst estimates. CNBC reported that the Covid vaccine generated $808 million in sales versus the $770.4 million analysts polled by StreetAccount were expecting, while Paxlovid booked $449 million against an estimate of $394.1 million. CNBC also noted that Pfizer expanded its multi-year cost-cutting program in August, targeting roughly $9.7 billion in net savings through 2029 to help offset the broader decline in Covid product revenue.

Cecile Guegan Named Permanent CFO

Pfizer confirmed that Cecile Guegan, who has held various finance leadership roles at the company over the past two decades, stepped into the permanent CFO role this month, according to CNBC. Guegan had served as interim CFO since August, after predecessor Dave Denton left to become Nike's CFO. The reporting reviewed for this brief does not detail how her appointment might shape Pfizer's capital allocation priorities or acquisition strategy going forward; no specific statements on M&A direction tied to the CFO transition were included in the available coverage.

Analyst Context: The Patent Cliff

Even with the guidance raise, some analysts have flagged structural headwinds facing Pfizer. In commentary cited by BioSpace, Guggenheim wrote that "the near-term story remains challenging for Pfizer given the multiple large patent expiration the company is facing between now and 2028," while adding that continued commercial and pipeline progress should help sustain investor interest. That assessment predates the Q3 report but underscores the backdrop against which this quarter's beat and raised guidance are being read: a company offsetting Covid-product erosion and looming patent expirations with strength in select branded drugs and cost discipline.

Bottom Line

Pfizer's third-quarter beat, upgraded EPS guidance, and permanent CFO appointment together suggest a company working to stabilize its earnings trajectory after a period of Covid-revenue decline and leadership transition. Per CNBC, Eliquis, Padcev, and even legacy Covid products beat Street estimates this quarter, but the low end of the company's revenue range would still be roughly flat to slightly lower versus 2025 revenue of $62.6 billion. Guggenheim commentary cited by BioSpace before this report pointed to multiple large patent expirations between now and 2028 as a near-term challenge. That combination is an interpretation of the reported figures, not a forecast: investors will likely look for more detail in coming quarters on what is specifically sustaining Eliquis and oncology demand, and on how Guegan's permanent appointment informs Pfizer's approach to further deal-making.